Deramiocel (CAP-1002)

Name: Deramiocel (CAP-1002) in Duchenne muscular dystrophy: Pathophysiology
Published: 2026-09-14T15:39:06-04:00

Duchenne muscular dystrophy

Manufacturer: Capricor Therapeutics
Regulatory submission: Class 2 BLA resubmission submitted February 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Pathophysiology

1 evidence topic · 1 source

Dystrophin deficiency and progressive degeneration

“Dystrophin deficiency leads to progressive muscle degeneration in Duchenne muscular dystrophy (DMD) patients.” (opens the source at this quote in a new tab)